In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Medical Services Patients & Visitors Health Library For Medical Professionals Quality About Us PhysicianLink
Text Size:  -   +  |  Print Page  |  Email Page

Esophageal Cancer



A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of ER2-Overexpressing Esophageal Adenocarcinoma.

For additional information please contact Nurdan IIgaz, Clinical Research Coordinator, at 859-260-6406.
REF# CBH 11-994